MYC and small cell lung carcinoma: Bulk transcriptomic analysis on the H146 (SCLC-A) cell line in vitro and Lx33 (SCLC-N) in vivo treated with cisplatin and simurosertib, as well as on the Lx761c (SCLC-N) in vivo treated with irinotecan and simurosertib (Supplementary Fig. s6a) consistently revealed global downregulation of genes involved in MYC signaling in the combo-treated tumors versus the chemotherapy monotherapy-treated tumors, similar to what was observed in the NE transformation models treated with simurosertib (Fig. 4a).